Xiaoqian Xu

A nationwide post-marketing survey of knowledge, attitude and practice toward human papillomavirus vaccine in general population: Implications for vaccine roll-out in mainland China

Shangying Hu, Xiaoqian Xu, Yanyang Zhang et al. · Vaccine · 2020 · 91 citations · Full text

Prevalence of dyslipidemia and associated risk factors among adults aged ≥35 years in northern China: a cross-sectional study

Yunfeng Xi, Liwei Niu, Ning Cao et al. · BMC Public Health · 2020 · 89 citations · Full text

Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study

Changfa Xia, Shangying Hu, Xiaoqian Xu et al. · The Lancet Public Health · 2019 · 85 citations · Full text

Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial

Fanghui Zhao, Ting Wu, Yuemei Hu et al. · The Lancet Infectious Diseases · 2022 · 85 citations

Vaccination, Vaccine Safety, L1 Virus-like-particle Vaccine +11

2,4-Diaryl-4,6,7,8-tetrahydroquinazolin-5(1H)-one derivatives as anti-HBV agents targeting at capsid assembly

Xuejun Zhu, Guoming Zhao, Xiao‐Ping Zhou et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 66 citations

Medicinal Chemistry, Antiviral Compound, Medicine +5